Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 821

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    267 result(s) found for: 821. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001483-39 Sponsor Protocol Number: IstitutoOncologicoVeneto Start Date*: 2014-03-06
    Sponsor Name:Istituto Oncologico Veneto
    Full Title: XELODA metronomic IN PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B
    Medical condition: PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019864-36 Sponsor Protocol Number: PML-DOC-1003 Start Date*: 2010-08-02
    Sponsor Name:University Hospital of Antwerp, Department of Respiratory Medicine
    Full Title: Open-label, prospective exploratory study to assess the effects of formoterol and beclometasone dipropionate combination therapy on central and peripheral airway dimensions in COPD patients.
    Medical condition: COPD (chronic obstructive pulmonary disease)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016502-16 Sponsor Protocol Number: PML_DOC_0905_/_ISSSYMB0020 Start Date*: 2009-12-02
    Sponsor Name:University Hospital Antwerp : Department Respiratory Medicine
    Full Title: A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbo...
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003249-16 Sponsor Protocol Number: PML_DOC_1102 Start Date*: 2012-01-06
    Sponsor Name:University Hospital of Antwerp
    Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003722-41 Sponsor Protocol Number: IOV–GB–1-2014-REGOMA Start Date*: 2015-04-24
    Sponsor Name:Istituto Oncologico Veneto – IOV‐IRCCS
    Full Title: Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004125-23 Sponsor Protocol Number: CCRG19-002 Start Date*: 2021-05-10
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma
    Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004124-42 Sponsor Protocol Number: CCRG19-001 Start Date*: 2023-04-18
    Sponsor Name:Antwerp University Hopsital
    Full Title: First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients
    Medical condition: histologically or cytologically confirmed solid tumor of the pancreas, esophagus, liver or ovaries that is advanced, recurrent or progressing after at least first-line anti-cancer treatment, or fo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004877-15 Sponsor Protocol Number: OPM-RADFORMIN-1801 Start Date*: 2018-06-11
    Sponsor Name:Antwerp University Hospital, Department Thoracic Oncology
    Full Title: Randomised phase II trial of definitive radiotherapy with or without metformin in patients with inoperable stage III non-small cell lung cancer
    Medical condition: Stage III non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025052 Lung cancer non-small cell stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004955-19 Sponsor Protocol Number: PARIDA-01/2013 Start Date*: 2014-09-03
    Sponsor Name:Azienda Ospedaliera di Padova
    Full Title: PARACETAMOL VERSUS IBUPROFEN FOR PATENT DUCTUS ARTERIOSUS TREATMENT IN PRETERM INFANTS.
    Medical condition: patent ductus arteriosus hemodynamically important
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10034190 PDA Repair patent ductus arteriosus LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004865-11 Sponsor Protocol Number: IV-FLEC Start Date*: 2022-03-21
    Sponsor Name:Win Medica Pharmaceuticals S.A.
    Full Title: Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation – a randomized, prospecti...
    Medical condition: Restoration of sinus rhythm in patients with recent AF onset
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001926-25 Sponsor Protocol Number: B300201316844 Start Date*: 2013-09-23
    Sponsor Name:Universitair Ziekenhuis Antwerpen
    Full Title: Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade
    Medical condition: Residual neuromuscular blockade and diphragm fatigue
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001098-15 Sponsor Protocol Number: CCRG14-001 Start Date*: 2015-10-13
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma
    Medical condition: Newly diagnosed glioblastoma (WHO grade IV) in adults, treated with surgical resection and chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004153-24 Sponsor Protocol Number: CRAD001JIT36T Start Date*: 2014-05-25
    Sponsor Name:Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche
    Full Title: MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control ...
    Medical condition: HR+ / HER2 negative metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006833-29 Sponsor Protocol Number: BPS-MR-PAH-202Amendment1Ireland Start Date*: 2009-06-29
    Sponsor Name:Lung LLC
    Full Title: An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001494-91 Sponsor Protocol Number: CCRG12-001 Start Date*: 2012-10-11
    Sponsor Name:Antwerp University Hospital
    Full Title: Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicenter randomized phase II trial
    Medical condition: Adult patients with acute myeloid leukemia in complete remission
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003247-70 Sponsor Protocol Number: UZAPED1 Start Date*: 2007-10-29
    Sponsor Name:Belgian Study Group for Pediatric Endocrinology
    Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height.
    Medical condition: predicted short stature
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066333 Idiopathic short stature LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003229-31 Sponsor Protocol Number: CCRG21-001 Start Date*: 2022-12-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000543-33 Sponsor Protocol Number: PANIB20140110 Start Date*: 2014-11-20
    Sponsor Name:Antwerp University Hospital
    Full Title: An open-label, randomized, controlled, multi-center, Phase II trial comparing Panitumumab versus Bevacizumab in combination with oxaliplatin - 5 FU (FOLFOX) first-line treatment according Ras ...
    Medical condition: metastatic unresectable colorectal cancer (mCRC) .
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002684-25 Sponsor Protocol Number: BSGPE2 Start Date*: 2012-08-06
    Sponsor Name:Antwerp University Hospital
    Full Title: Efficacy and safety of a 4 year pubertal therapy with growth hormone (somatropine Omnitrope) or an aromatase inhibitor (letrozole Femara) or the combination of both in boys with a short predicted h...
    Medical condition: boys with idiopathic short adult stature defined as a predicted adult height below or equal to 164.0 cm ( -2.5 SDS) without a known cause
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10066333 Idiopathic short stature LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004148-23 Sponsor Protocol Number: 1218.22 Start Date*: 2013-10-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PL (Completed) BG (Completed) HR (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:47:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA